John G Ullman & Associates Inc Regeneron Pharmaceuticals, Inc. Transaction History
John G Ullman & Associates Inc
- $631 Million
- Q4 2024
A detailed history of John G Ullman & Associates Inc transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, John G Ullman & Associates Inc holds 3,315 shares of REGN stock, worth $2.35 Million. This represents 0.37% of its overall portfolio holdings.
Number of Shares
3,315Holding current value
$2.35 Million% of portfolio
0.37%Shares
8 transactions
Others Institutions Holding REGN
# of Institutions
1,484Shares Held
83.7MCall Options Held
1.22MPut Options Held
1.5M-
Vanguard Group Inc Valley Forge, PA9.32MShares$6.62 Billion0.18% of portfolio
-
Black Rock Inc. New York, NY8.45MShares$6 Billion0.2% of portfolio
-
Jpmorgan Chase & CO New York, NY7.49MShares$5.32 Billion0.64% of portfolio
-
State Street Corp Boston, MA4.9MShares$3.48 Billion0.21% of portfolio
-
Capital World Investors Los Angeles, CA4.3MShares$3.05 Billion0.72% of portfolio
About REGENERON PHARMACEUTICALS, INC.
- Ticker REGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 107,190,000
- Market Cap $76.1B
- Description
- Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...